{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koren J"],"funding":["European Structural and Investment Funds","Slovak Research and Development Agency","European Regional Development Fund"],"pagination":["1538"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9686475"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(11)"],"pubmed_abstract":["Carbapenem-resistant (CR) <i>Klebsiella pneumoniae</i> represents an urgent worldwide threat. We focused on CR <i>K. pneumoniae</i> in selected facilities of the University Hospital Bratislava (UHB) to investigate sequence types (STs), clonal relatedness, and antimicrobial resistance. Suspected carbapenem-nonsusceptible <i>K. pneumoniae</i> strains were obtained from hospitalized patients. Further examination included carbapenemase confirmation, cgMLST, and quantitative susceptibility testing. Of the total 41 CR <i>K. pneumoniae</i> strains, 26 (63.4%) were determined as ST11 in hospital No. 1; of these ST11, 22 (84.6%) were found in the first internal clinic. Six (14.6%) ST258 and three (7.3%) ST584 occurred in hospital No. 2; the most, i.e., four (66.7%), ST258 were detected in the geriatric clinic. In hospital No. 3, we found two (4.8%) ST584 and one (2.4%) ST258. Of the ST11 set, 24 (92.3%) produced NDM-1. Furthermore, seven (87.5) ST258 and five (100%) ST584 strains generated KPC-2. Antimicrobial resistance was as follows: ertapenem 97.6%, meropenem 63.4%, tigecycline 7.3%, eravacycline 7.3%, and colistin 2.5%. We revealed a presumably epidemiological association of ST11 with transmission, particularly in the first internal clinic of hospital No. 1, while ST258 and ST584 were related to interhospital dissemination between medical facilities No. 2 and No. 3. It is essential to prevent the circulation of these pathogens within and between healthcare facilities."],"journal":["Antibiotics (Basel, Switzerland)"],"pubmed_title":["Next-Generation Sequencing of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains Isolated from Patients Hospitalized in the University Hospital Facilities."],"pmcid":["PMC9686475"],"funding_grant_id":["SRDA-20-0413","ITMS: 313011T431","NFP313010V344"],"pubmed_authors":["Maliar T","Koren J","Liptakova A","Drahovska H","Hubenakova Z","Andrezal M"],"additional_accession":[]},"is_claimable":false,"name":"Next-Generation Sequencing of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains Isolated from Patients Hospitalized in the University Hospital Facilities.","description":"Carbapenem-resistant (CR) <i>Klebsiella pneumoniae</i> represents an urgent worldwide threat. We focused on CR <i>K. pneumoniae</i> in selected facilities of the University Hospital Bratislava (UHB) to investigate sequence types (STs), clonal relatedness, and antimicrobial resistance. Suspected carbapenem-nonsusceptible <i>K. pneumoniae</i> strains were obtained from hospitalized patients. Further examination included carbapenemase confirmation, cgMLST, and quantitative susceptibility testing. Of the total 41 CR <i>K. pneumoniae</i> strains, 26 (63.4%) were determined as ST11 in hospital No. 1; of these ST11, 22 (84.6%) were found in the first internal clinic. Six (14.6%) ST258 and three (7.3%) ST584 occurred in hospital No. 2; the most, i.e., four (66.7%), ST258 were detected in the geriatric clinic. In hospital No. 3, we found two (4.8%) ST584 and one (2.4%) ST258. Of the ST11 set, 24 (92.3%) produced NDM-1. Furthermore, seven (87.5) ST258 and five (100%) ST584 strains generated KPC-2. Antimicrobial resistance was as follows: ertapenem 97.6%, meropenem 63.4%, tigecycline 7.3%, eravacycline 7.3%, and colistin 2.5%. We revealed a presumably epidemiological association of ST11 with transmission, particularly in the first internal clinic of hospital No. 1, while ST258 and ST584 were related to interhospital dissemination between medical facilities No. 2 and No. 3. It is essential to prevent the circulation of these pathogens within and between healthcare facilities.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-25T20:58:36.359Z","creation":"2025-04-06T08:38:50.918Z"},"accession":"S-EPMC9686475","cross_references":{"pubmed":["36358193"],"doi":["10.3390/antibiotics11111538"]}}